Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Principia Biopharma Inc. manages 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 6 distinct art units and 7 distinct examiners. This ratio of examiners to actions indicates that each pending matter is being handled by a different individual, preventing a concentration of the workload. The 7 pending office actions are thus subject to 7 different sets of examiner preferences.
The busiest examiner, COLEMAN, BRENDA LIBBY, is responsible for 1 pending office action. With 7 distinct examiners involved, the prosecution strategy must account for a range of individual examiner approaches. The involvement of 6 distinct art units suggests that the company's research is being evaluated by several different specialized groups. This diversity in examination requires a highly individualized approach to each of the 7 pending office actions currently in the portfolio within the Biotechnology & Pharmaceuticals technology area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (29%) |
| §112 only | 2 (29%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 1 | 74.8% | +15.7% |
| MERCIER, MELISSA S | 1 | 72.1% | +5.7% |
| HERNANDEZ, JACKSON J | 1 | 50.7% | +40.5% |
| FETTEROLF, BRANDON J | 1 | 51.8% | +18.6% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.7% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 65.4% | +36.8% |
| HUI, SAN MING R | 1 | 59.6% | +20.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18789827 | PROCESS OF MAKING 2-[(3R)-2-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4[4-(OXETAN-3-YL)PIPERAZIN-1-YL]-PENT-2-ENENITRILE AND SOLVATE FORMS THEREOF | HERNANDEZ, JACKSON J | — |
| 18377540 | THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MULTIPLE SCLEROSIS | RODRIGUEZ-GARCIA, VALERIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17920147 | Treatment of Acute Respiratory Distress Syndrome and Other Disorders Involving Cytokine Storm Using BTK Inhibitors | RZECZYCKI, PHILLIP MATTHEW | 53d |
| 18864343 | THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY DISEASE (MOGAD) | COLEMAN, BRENDA LIBBY | — |
| 18789827 | PROCESS OF MAKING 2-[(3R)-2-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4[4-(OXETAN-3-YL)PIPERAZIN-1-YL]-PENT-2-ENENITRILE AND SOLVATE FORMS THEREOF | HERNANDEZ, JACKSON J | — |
| 18756019 | METHODS FOR TREATING PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA IN CHILDREN, ADOLESCENTS AND ADULTS BY ADMINISTERING (R)-2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE | FETTEROLF, BRANDON J | — |
| 18377540 | THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MULTIPLE SCLEROSIS | RODRIGUEZ-GARCIA, VALERIE | — |
| 17957073 | Method of Treating Pemphigus by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1624 | 1 |
| 1615 | 1 |
| 1626 | 1 |
| 1621 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18864343 | THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY DISEASE (MOGAD) | COLEMAN, BRENDA LIBBY | 1624 | §112 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18889671 | Topical Pharmaceutical Compositions Comprising 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile | MERCIER, MELISSA S | 1615 | §112 | Non-Final OA | — | Pending | Sep 19, 2024 |
| 18789827 | PROCESS OF MAKING 2-[(3R)-2-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4[4-(OXETAN-3-YL)PIPERAZIN-1-YL]-PENT-2-ENENITRILE AND SOLVATE FORMS THEREOF | HERNANDEZ, JACKSON J | 1627 | §103§112Other | Non-Final OA | — | Pending | Jul 31, 2024 |
| 18756019 | METHODS FOR TREATING PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA IN CHILDREN, ADOLESCENTS AND ADULTS BY ADMINISTERING (R)-2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE | FETTEROLF, BRANDON J | 1626 | §102§103DP | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18377540 | THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MULTIPLE SCLEROSIS | RODRIGUEZ-GARCIA, VALERIE | 1621 | §103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 17920147 | Treatment of Acute Respiratory Distress Syndrome and Other Disorders Involving Cytokine Storm Using BTK Inhibitors | RZECZYCKI, PHILLIP MATTHEW | 1625 | §103 | Final Rejection | 53d | Pending | Oct 20, 2022 |
| 17957073 | Method of Treating Pemphigus by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile | HUI, SAN MING R | 1627 | §103 | Non-Final OA | — | Pending | Sep 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPrincipia Biopharma Inc. has 7 pending office actions as of November 2026, spread across 6 art units and 7 examiners.
Brenda Libby Coleman has the most, with 1 of Principia Biopharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.